Physician profile
Sue E Espinal
NPI 1811961931
$595.35
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $426 · 2020: $141 · 2021: $28.48.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $229.60 | 2019-2020 | |
| Amag Pharmaceuticals, INC. | $93.90 | 2019 | |
| Exeltis, USA INC. | $78.90 | 2019-2020 | |
| Mylan Pharmaceuticals INC. | $41.05 | 2019 | |
| Allergan, INC. | $34.94 | 2019 | |
| Hologic Sales and Service, LLC | $20.44 | 2019 | |
| Lupin INC. | $18.37 | 2020 | |
| Therapeuticsmd, INC. | $14.26 | 2021 | |
| Myovant Sciences INC. | $14.22 | 2021 | |
| Coopersurgical, INC. | $13.82 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.46 | 2020 | |
| Pfizer INC. | $11.29 | 2020 | |
| Daiichi Sankyo INC. | $11.10 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sue Espinal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.